AZN Jun 2024 75.000 call
| Previous close | 2.1700 |
| Open | 2.8700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 75.00 |
| Expiry date | 2024-06-07 |
| Day's range | 2.1700 - 2.8700 |
| Contract range | N/A |
| Volume | |
| Open interest | 46 |
Fool.co.ukWhere is the UK stock market headed for the rest of 2024?
I've been searching high and low to uncover insightful opinions from professionals about where the UK stock market is headed in 2024. The post Where is the UK stock market headed for the rest of 2024? appeared first on The Motley Fool UK.
BenzingaWhy Is AstraZeneca Stock Trading Lower On Tuesday?
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated wi
GlobeNewswireCellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and g
